이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AngioDynamics 배당금

배당금 기준 확인 0/6

AngioDynamics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$4.80
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

AngioDynamics: A Story To Monitor

May 14

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 09

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Apr 06

AngioDynamics: Restructuring Initiative May Not Go Far Enough

Jan 14

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Oct 12

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Mar 31

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

Oct 06

Shareholders May Not Be So Generous With AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Compensation And Here's Why

Oct 28

Is AngioDynamics (NASDAQ:ANGO) Weighed On By Its Debt Load?

Oct 07

AngioDynamics: Focusing On Three Credible Growth Drivers And Targeting Growth Acceleration

Jul 20

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 ANGO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ANGO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

AngioDynamics 시장 대비 배당 수익률

ANGO 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (ANGO)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Medical Equipment)	1.8%
3년 후 애널리스트 예측 (ANGO)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ANGO 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ANGO 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ANGO 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: ANGO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

AngioDynamics 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

AngioDynamics: A Story To Monitor

CEO, President & Director recently bought US$67k worth of stock

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Price target decreased by 10.0% to US$13.50

Insufficient new directors

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024

Angiodynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc

AngioDynamics, Inc. to Report Q3, 2024 Results on Apr 04, 2024

Angiodynamics, Inc. Announces Board Changes

Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease

AngioDynamics: Restructuring Initiative May Not Go Far Enough

AngioDynamics, Inc. Announces Manufacturing Operations Restructuring

David D. Helsel to Leave AngioDynamics, Inc. as Senior Vice President of Global Operations and R&D, Effective January 12, 2024

AngioDynamics, Inc. to Report Q2, 2024 Results on Jan 05, 2024

AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary Embolism

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023

Price target increased by 12% to US$17.33

AngioDynamics, Inc. to Report Q1, 2024 Results on Oct 04, 2023

AngioDynamics, Inc. Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

Angiodynamics, Inc. Completes Enrollment for Preserve Clinical Study

CEO, President & Director exercised options and sold US$102k worth of stock

AngioDynamics, Inc. Announces Addition of Lorinda Burgess to Board of Directors

Consensus EPS estimates fall by 52%, revenue upgraded

AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

AngioDynamics, Inc. to Report Q4, 2023 Results on Jul 12, 2023

New minor risk - Profitability

Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million.

Forecast to breakeven in 2026

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Price target decreased by 22% to US$20.00

Key Executive recently sold US$60k worth of stock

Price target decreased to US$24.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AngioDynamics, Inc. Reaffirms Revenue Guidance for Fiscal 2023

AngioDynamics, Inc. to Report Q2, 2023 Results on Jan 05, 2023

Price target decreased to US$26.50

Insufficient new directors

AngioDynamics, Inc. Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism

CEO, President & Director recently bought US$150k worth of stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

AngioDynamics, Inc. Reaffirms Earnings Guidance for the Year 2023

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold

AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022

AngioDynamics, Inc. to Report Q1, 2023 Results on Oct 06, 2022

Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?

Key Executive recently sold US$112k worth of stock

Executive VP & CFO exercised options and sold US$67k worth of stock

Consensus forecasts updated

Price target decreased to US$31.00

Forecast to breakeven in 2025

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2023

AngioDynamics Non-GAAP EPS of $0.01 in-line, revenue of $87M beats by $4.09M

CEO, President & Director exercised options and sold US$176k worth of stock

AngioDynamics, Inc. to Report Q4, 2022 Results on Jul 12, 2022

Key Executive recently sold US$79k worth of stock

Price target increased to US$36.00

Independent Non-Executive Chairman exercised options to buy US$136k worth of stock.

Insufficient new directors

Independent Non-Executive Chairman exercised options to buy US$140k worth of stock.

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Price target increased to US$36.00

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

AngioDynamics Shows Progress In Still-Challenging Times

AngioDynamics, Inc. Provides Earnings Guidance for the Year 2022

Is AngioDynamics (NASDAQ:ANGO) Using Debt Sensibly?

AngioDynamics - Progress Despite Margin And Pandemic Challenges